Insulin is a hormone crucial for regulating blood glucose levels in the body. For individuals with diabetes, who either do not produce enough insulin (Type 1 diabetes) or have developed resistance to insulin (Type 2 diabetes), exogenous insulin therapy is essential for maintaining optimal blood sugar control. Over the years, advancements in biotechnology have led to the development of various types of insulin formulations with different onset, peak, and duration of action profiles. This article aims to explore the different types of insulins available, their characteristics, indications for use, and considerations for therapy in diabetes management.
1. Physiology and Role of Insulin
Insulin is produced by beta cells in the pancreas and plays a central role in glucose metabolism. Its primary functions include:
- Facilitating Glucose Uptake: Insulin facilitates the uptake of glucose into cells, particularly muscle, fat, and liver cells, where it is utilized for energy production or stored as glycogen.
- Inhibiting Glucose Production: Insulin suppresses glucose production in the liver, preventing excessive glucose release into the bloodstream.
- Promoting Protein Synthesis: Insulin promotes the synthesis of proteins and inhibits protein breakdown, aiding in tissue repair and growth.
- Regulating Lipid Metabolism: Insulin influences lipid metabolism by promoting fat storage in adipose tissue and inhibiting lipolysis (breakdown of fats).
In diabetes, insufficient insulin action leads to hyperglycemia (high blood sugar), which can lead to various complications if left untreated.
2. Types of Insulin Based on Duration of Action
Insulin formulations can be categorized based on their duration of action, which refers to how long they remain active in the body after administration. These categories include:
Rapid-Acting Insulins
Rapid-acting insulins have a quick onset of action, reaching peak blood levels within 30 minutes to 3 hours after injection. They are typically used to manage postprandial (after-meal) blood glucose spikes and are administered shortly before or immediately after meals.
- Insulin Lispro (Humalog): A synthetic analog of human insulin where the proline at position B28 and lysine at position B29 are reversed. This modification prevents the formation of hexamers, making it absorb more quickly than regular insulin. It starts working within 15 minutes and peaks in about 1 to 2 hours. The duration of action is approximately 3 to 4 hours.
- Insulin Aspart (NovoLog/NovoRapid): Another synthetic insulin analog that works similarly to insulin lispro, with an onset of action within 10 to 20 minutes. It peaks in about 1 to 3 hours and lasts for about 3 to 5 hours.
- Insulin Glulisine (Apidra): A third rapid-acting synthetic insulin analog that starts working within 10 to 15 minutes, peaks in about 1 hour, and lasts for approximately 3 to 4 hours.
Rapid-acting insulins are suitable for individuals who require precise control over postprandial glucose levels and flexibility in meal timing.
Short-Acting (Regular) Insulin
Short-acting insulin, also known as regular insulin, has a slower onset of action compared to rapid-acting insulins but lasts longer.
- Regular Insulin (Humulin R, Novolin R): This is identical to human insulin and takes about 30 minutes to start working. It peaks in 2 to 4 hours and remains active for about 6 to 8 hours.
Short-acting insulin is commonly used to manage blood glucose levels between meals and overnight. It is also administered intravenously in hospital settings for tight glycemic control.
Intermediate-Acting Insulins
Intermediate-acting insulins have a slower onset and longer duration of action compared to rapid-acting and short-acting insulins. They provide basal insulin coverage, helping to maintain blood glucose levels between meals and overnight.
- Neutral Protamine Hagedorn (NPH) Insulin (Humulin N, Novolin N): This is an intermediate-acting insulin that contains zinc and protamine, which delays its absorption into the bloodstream. It typically starts working within 1 to 2 hours, peaks in about 4 to 12 hours, and can last for up to 18 hours. NPH insulin is often used in combination with rapid-acting insulins to provide both basal and mealtime insulin coverage.
Intermediate-acting insulins are suitable for individuals who require a longer-acting insulin to manage blood glucose levels throughout the day and night.
Long-Acting Insulins
Long-acting insulins have a slow and steady release, providing basal insulin coverage over an extended period, usually 24 hours. They help maintain stable blood glucose levels between meals and overnight without the need for frequent injections.
- Insulin Glargine (Lantus, Basaglar, Toujeo): This is a synthetic analog of human insulin that forms microprecipitates at the injection site, resulting in a slow and continuous release of insulin into the bloodstream. Glargine has no pronounced peak and provides a steady level of insulin activity over 24 hours. Newer formulations such as Toujeo have an extended duration of action beyond 24 hours.
- Insulin Detemir (Levemir): This is another long-acting insulin analog that binds to albumin in the bloodstream, prolonging its duration of action. Detemir typically starts working within 1 to 2 hours, peaks in about 6 to 8 hours, and lasts up to 24 hours.
Long-acting insulins are suitable for individuals who require consistent basal insulin coverage with once-daily or twice-daily injections.
3. Combination Insulin Therapies
Combination insulin therapies involve mixing different types of insulins to provide both basal and prandial (mealtime) insulin coverage in a single injection. Common combinations include:
- Biphasic Insulin (Mixtures): These insulins combine intermediate-acting and short-acting insulins in varying proportions. They are designed to provide both basal and prandial insulin coverage, simplifying insulin therapy for some individuals.
- Examples: Biphasic insulin preparations like Humulin 30/70, Novolin 30R, and NovoMix 30 contain 30% rapid-acting insulin and 70% intermediate-acting insulin. These mixtures are typically taken before breakfast and dinner to cover mealtime insulin needs.
Combination therapies are useful for individuals who prefer fewer injections and simplified insulin regimens while still achieving optimal blood glucose control throughout the day.
4. Ultra-Rapid Acting Insulins
Recent advancements in insulin technology have led to the development of ultra-rapid acting insulins, which have an even faster onset of action than traditional rapid-acting insulins.
- Insulin Fiasp (Faster Aspart): This is an ultra-rapid acting insulin analog that contains niacinamide (vitamin B3), which enhances the absorption rate of insulin aspart. Fiasp starts working within 5 to 10 minutes after injection, peaks in about 1 hour, and lasts for approximately 3 to 5 hours.
Ultra-rapid acting insulins are particularly beneficial for individuals who require rapid control of postprandial glucose levels and flexibility in mealtime insulin dosing.
5. Inhalable Insulin
Inhalable insulin offers an alternative to injectable insulin therapy for some individuals with diabetes. It is administered via an inhaler device and absorbed through the lungs into the bloodstream.
- Insulin Afrezza: This rapid-acting inhaled insulin is used at the beginning of meals to control postprandial glucose levels. Afrezza starts working within 12 to 15 minutes, peaks in about 30 to 90 minutes, and lasts for approximately 3 to 5 hours.
Inhalable insulin may be suitable for individuals who prefer a non-injectable insulin option and have good lung function. However, it is not recommended for individuals with chronic lung diseases such as asthma or COPD.
6. Biosimilar Insulins
Biosimilar insulins are biologic products that are highly similar to and have no clinically meaningful differences from an existing FDA-approved reference product. They provide more affordable alternatives to brand-name insulins while maintaining equivalent safety and efficacy.
- Examples: Biosimilar insulins include products like Basaglar (insulin glargine biosimilar) and Semglee (insulin glargine biosimilar).
Biosimilar insulins undergo rigorous testing to demonstrate similarity in terms of pharmacokinetics, pharmacodynamics, and clinical efficacy compared to their reference products.
Considerations for Insulin Therapy
When selecting an insulin regimen for individuals with diabetes, several factors must be considered:
- Type of Diabetes: The type of diabetes (Type 1 vs. Type 2) and individual insulin requirements influence the choice of insulin regimen.
- Glycemic Goals: Individualized glycemic targets based on age, duration of diabetes, presence of complications, and lifestyle factors guide insulin therapy.
- Injection Frequency: Some individuals may prefer fewer injections with long-acting insulins, while others may benefit from the flexibility of multiple daily injections with rapid-acting or ultra-rapid acting insulins.
- Mealtime Flexibility: Insulin formulations with rapid onset and short duration of action provide flexibility in adjusting insulin doses according to mealtime carbohydrate intake.
- Patient Preference: Patient preferences, lifestyle considerations, and adherence to insulin therapy play crucial roles in selecting the most suitable insulin regimen.
Conclusion
The availability of various insulin formulations with different onset, peak, and duration of action profiles has revolutionized diabetes management. From rapid-acting insulins for immediate postprandial glucose control to long-acting insulins for basal coverage, healthcare providers can tailor insulin therapy to meet individualized patient needs. Ongoing advancements in insulin technology, including ultra-rapid acting insulins and biosimilar options, continue to expand treatment options and improve glycemic outcomes for individuals living with diabetes. By understanding the characteristics and considerations of each type of insulin, healthcare providers can empower patients to achieve optimal blood glucose control and enhance their quality of life.
Related topics:
What’s the 4 most common types of diabetes
